Of the 9,724 high-confidence p63 binding sites (identified with both antibodies), 5,933 sites were shared between SCC104 and SCC152 cell lines, providing a strong list of bona-fide p63 targets in HPV+ HNSCC. The gene discussed is TP63; the disease is head and neck squamous cell carcinoma.